Showing results (241-250 of 257) with videos related to
Sort By:
Pageof 26
JAMA|January 31, 2008
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinomaAaron J Schetter, Suet Yi Leung, Jane J Sohn, et al.Cancer Research|October 28, 2010
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinomaJohannes Voortman, Akiteru Goto, Jean Mendiboure, et al.The American Journal of Surgical Pathology|February 6, 2023
Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and PancreaticoduodenectomyAaron J Sohn, Mehran Taherian, Matthew H G Katz, et al.ESMO Open|August 10, 2023
Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancerG Viale, M Basik, N Niikura, et al.Plos One|September 13, 2012
Macrophages, nitric oxide and microRNAs are associated with DNA damage response pathway and senescence in inflammatory bowel diseaseJane J Sohn, Aaron J Schetter, Harris G Yfantis, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 18, 2013
Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancerJ-M Sun, Y C Ahn, E K Choi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2026
OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast CancerB Xu, H Jeong, T Sun, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2024
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3M P Goetz, M Toi, J Huober, et al.ESMO Open|September 6, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 studyH S Rugo, M Oliveira, S J Howell, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 30, 2013
A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitorsSue J Sohn, Kathy Barrett, Anne Van Abbema, et al.Pageof 26